secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001104659-23-017571
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q1 revenues $5.3M (+26% YoY); operating loss narrows to $1.2M
-------------------------------------------------------------------------

- Total revenues $5.3M vs $4.2M in prior-year period; clinical lab service rev $4.5M (+41% YoY).
- Gross profit $2.4M (45% margin) vs $1.1M (27%), driven by higher testing volumes and cost management.
- Operating loss $1.2M vs $4.7M loss a year ago; Adjusted EBITDA -$1.1M vs -$2.7M.
- Cash $12.9M at Dec 31, 2022; 7.3M warrants outstanding with potential proceeds of ~$26.6M.
- cGMP facility build-out initiated within HQ; PGx validation package to be filed with NYSDOH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465923017571/0001104659-23-017571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465923017571/tm236000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-017571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer